

# Sarborg Completes Development of Proprietary AI Signature Agent Initially Focused on Drug–Disease Matching

WILMINGTON, De -- December 8, 2025 -- Sarborg Limited (“**Sarborg**” or the “**Company**”), today announced the completion of development of its proprietary, AI Signature Agent, initially focused on matching drug and disease signatures within the pharmaceutical sector.

The Signature Agent has been designed to analyse and compare structured biological signatures derived from drugs and diseases, with the objective of identifying potential therapeutic matches. By encoding gene expression patterns, pathway activity and other biological features into structured signatures, the platform can generate a ranked list of potential disease indications for a given drug candidate.

This process of identifying potential repurposing opportunities can be completed in minutes, representing a significant acceleration compared to traditional pharmaceutical discovery workflows, which often require several years to identify and validate promising preclinical candidates.

The platform operates by systematically pairing a drug signature against a curated reference set of disease signatures and applying multi-layered connectivity mapping, gene and pathway analysis to determine relative alignment. The output is a prioritised ranking of indications based on scientific fit and signal strength, providing both research and commercial insight at the screening stage.

The Company intends to deploy the Signature Agent both internally and with prospective pharmaceutical partners, initially as a signature analysis and opportunity-screening tool. Over time, Sarborg expects the platform to serve as a core decision-support layer across research, licensing and strategic development activities.

Sarborg is built on the principle that biological, chemical and industrial signatures can function as a universal data language to identify, interpret and generate high-value opportunities across multiple sectors. By analysing, matching and learning from large-scale signature datasets, Sarborg’s agents create a continuously evolving network of intelligence-driven insights that inform scientific and commercial decision-making.

The Company will continue to refine its pharmaceutical signature libraries while exploring additional domains in which structured signature datasets exist.

## About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

### Investors & Media:

[info@sarborg.com](mailto:info@sarborg.com)

[www.sarborg.com](http://www.sarborg.com)